SYGNIS AG announced that it has signed a non-exclusive distribution agreement for the commercialization of SYGNIS' proprietary product portfolio in Taiwan with Welgene Biotech Co., Ltd. Under the terms of the agreement, SYGNIS has granted Welgene Biotech the non-exclusive rights to promote, market and sell TruePrime(TM) products for primer-free WGA as well as SunScript(TM) thermostable reverse transcriptase kits for the translation of RNA into DNA to scientists working in the wide field of molecular biology in Taiwan. TruePrime(TM) products are based on the combination of SYGNIS' proprietary DNA primase 'TthPrimPol' and Phi29 polymerase, which allows the amplification of total genomic DNA from smallest amounts of samples down to single cells without the need of random synthetic primers. SYGNIS' SunScript(TM) product line covers a series of kits based on a novel proprietary engineered reverse transcriptase (RT) which is one of the most thermostable and fastest enzymes commercially available.

RTs are commonly used in molecular biology to convert genetic information from RNA molecules back to DNA, enabling a number of downstream analyses of RNA molecules using DNA analysis methods such as NGS or polymerase chain reaction (PCR) in gene expression profiling and molecular diagnostics.